Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Indian share markets remain buoyant
Mon, 27 May 01:30 pm

Backed by strong buying across index heavyweights, Indian share markets traded firmly above the dotted line in the post-noon trading session. Barring stocks from the capital goods and auto sectors, all the sectoral indices are trading in the green with consumer durables, oil and gas and Pharma stocks leading the gains.

BSE-Sensex is up 170 points and NSE-Nifty is trading 43 points up. BSE Mid Cap is trading 0.7% up and BSE Small Cap index is trading up by 0.5%. The rupee is trading at 55.5 to the US dollar.

Majority of the energy stocks are trading in the green, with Reliance Industries Ltd (RIL) and Essar Oil being among the top gainers. As per a leading financial daily, RIL has announced that its partners British Petroleum (BP) and NIKO have made a significant gas and condensate discovery in KG-D6 block. The discovery named D-55 lies over 2,000 meters below the already producing reservoirs in D1-D3 gas fields. The discovery has been notified to the government and the Management Committee of the block. Reportedly, RIL has discovered 18 gas fields in the KG-D6 block of which only D1 & D3 have been put to production whereas satellite fields are being planned to be developed.

Most of the domestic pharma stocks desc are trading in the green with Wockhardt Ltd and Sun Pharmaceuticals Ltd leading among the pack of gainers. Sun Pharma's subsidiary Taro Pharma declared its March 2013 quarter results. Net sales grew by 14% YoY, however sales volume was marginally down for the quarter. Gross margins were at 72.4% during 4QFY13 vs. 68.3% during 4QFY12. On the EBITDA front, operating income decreased by 38.2% due to onetime litigation expenses amounting to US$ 22 m. Adjusting the one time expenditure, operating income witnessed growth of 28.7% during 4QFY13. Net profits grew by 4.5% YoY for the said quarter. Sun Pharma was trading up by 3.5%.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian share markets remain buoyant". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.